Ocular Therapeutix (NSDQ:OCUL) said today that it landed a licensing deal with Regeneron (NSDQ:REGN) to develop a sustained-release version of Regeneron’s aflibercept (Eylea), a therapy for wet age-related macular degeneration.
The deal will cost Regeneron $10 million up front, and in total could cost the Tarrytown, N.Y.-based biotech $315 million if regulatory and commercialization milestones are met.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix inks $315 deal with Regeneron appeared first on MassDevice.
from MassDevice http://ift.tt/2d9ylw6
Cap comentari:
Publica un comentari a l'entrada